Caplin Steriles, a subsidiary of Caplin Point, has received FDA approval for Calcium Gluconate Injections, signifying a key step towards penetrating the US market.

Caplin Point's calcium gluconate injection has received approval from the FDA, allowing it to be used for treating acute, symptomatic hypocalcemia in the US.

Caplin Point's subsidiary has received FDA approval for a generic Calcium Gluconate Injection, matching Fresenius Kabi's product. This move could potentially challenge the market with an estimated $71M in US sales for FY26.